Financial Performance - The company reported a revenue of HKD 922,501,000 for the six months ending June 30, 2024, a decrease of 2.9% compared to HKD 950,263,000 for the same period in 2023[2]. - The adjusted profit attributable to equity holders for the period was HKD 30,763,000, representing a 31.7% increase from HKD 23,351,000 in the previous year[5]. - The operating profit increased to HKD 73,423,000, up 35.6% from HKD 54,150,000 in the prior period[4]. - The EBITDA for the period was HKD 68,393,000, compared to HKD 57,173,000 for the same period last year, reflecting a significant growth[5]. - The company recorded a net profit of HKD 48,636,000 for the period, up 28.0% from HKD 37,997,000 in the previous year[5]. - The gross profit margin for the period was 31.3%, slightly down from 31.6% in the previous year[2]. - Total revenue for the first half of 2024 was HKD 922.5 million, a slight decrease of 2.9% compared to HKD 950.3 million in the same period of 2023[41]. - The company's profit attributable to equity holders for the first half of 2024 increased by 3.4% to HKD 30.8 million, compared to HKD 29.8 million in the same period last year[36]. Revenue Breakdown - Revenue from ophthalmology services decreased to HKD 586,873,000 from HKD 630,240,000 year-over-year[18]. - Dental services revenue increased significantly to HKD 246,400,000 from HKD 192,521,000, reflecting a growth of approximately 28%[18]. - Revenue from core medical services slightly decreased by 0.9% to HKD 922.5 million, down from HKD 930.8 million in the previous year[36]. - Revenue from Hong Kong medical services dropped by 9.0% to HKD 427.1 million, primarily due to a 6.6% decrease in ophthalmology services revenue[42]. - Revenue from mainland China increased by 7.4% to HKD 495.4 million, with an 11.8% increase when calculated in RMB[43]. - Revenue from dental services in Shenzhen rose by 33.3% to HKD 224.7 million, driven by increased cross-border consumption[46]. - Revenue from mainland China accounted for 53.7% of total revenue in the first half of 2024, up from 48.6% in the same period of 2023, due to a 33.3% increase in dental service revenue[50]. Expenses and Costs - Total expenses for the six months ended June 30, 2024, were HKD 853,372,000, down from HKD 897,920,000 in the same period last year, reflecting a decrease of approximately 5%[26]. - The total administrative expenses for the period were HKD 159,356,000, reflecting the costs associated with managing the diversified operations[21]. - Sales expenses reduced by 12.2% to HKD 60.6 million, down from HKD 69.1 million in the previous year[65]. - Financial expenses increased from HKD 0.4 million for the six months ended June 30, 2023, to HKD 4.8 million for the first half of 2024, primarily due to decreased bank deposit interest income and increased interest expenses on lease liabilities[69]. Assets and Liabilities - The company’s total assets as of June 30, 2024, were HKD 2,774,331,000, an increase from HKD 2,748,635,000 at the end of 2023[7]. - Total liabilities rose to HKD 773,325,000 from HKD 755,349,000, indicating a growth in financial obligations[10]. - Total equity as of June 30, 2024, is HKD 2,001,006,000, an increase from HKD 1,993,286,000 as of December 31, 2023[8]. Strategic Initiatives - The company plans to expand its market presence and invest in new product development to drive future growth[3]. - The company plans to diversify its operations further, with a new reporting structure effective January 1, 2024, focusing on five reportable segments[21]. - The company plans to focus on ophthalmic services in Hong Kong and cities in mainland China, while further developing cross-border medical services in Shenzhen, including establishing a hospital in Luohu[74]. - The company has opened a new dental hospital near the Luohu and Futian border, enhancing its business expansion strategy[39]. Shareholder Information - The company did not declare an interim dividend for the six months ended June 30, 2024, consistent with the previous year[33]. - The board does not recommend any interim dividend for the six months ended June 30, 2024[75]. Other Financial Information - The income tax expense for the period was HKD 19,757,000, slightly up from HKD 19,176,000 in the previous year[29]. - Basic earnings per share increased to HKD 2.48 from HKD 2.36, representing a growth of approximately 5.1%[31]. - The company recorded a loss from joint ventures of HKD 241,000 for the six months ended June 30, 2024[21]. - The company is currently evaluating the financial impact of new accounting standards that will take effect in future fiscal years[17].
希玛医疗(03309) - 2024 - 中期业绩